Citizens Financial Group Inc. RI Trims Position in The Cooper Companies, Inc. (NASDAQ:COO)

Citizens Financial Group Inc. RI decreased its position in The Cooper Companies, Inc. (NASDAQ:COO) by 5.1% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 6,254 shares of the medical device company’s stock after selling 334 shares during the quarter. Citizens Financial Group Inc. RI’s holdings in Cooper Companies were worth $575,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors purchased a new stake in shares of Cooper Companies in the 4th quarter worth $691,000. Highland Capital Management LLC purchased a new stake in Cooper Companies in the fourth quarter worth about $4,004,000. Caprock Group LLC purchased a new stake in Cooper Companies in the fourth quarter worth about $282,000. Franklin Resources Inc. raised its stake in shares of Cooper Companies by 194.0% in the third quarter. Franklin Resources Inc. now owns 48,892 shares of the medical device company’s stock worth $5,265,000 after buying an additional 32,260 shares during the period. Finally, Principal Financial Group Inc. lifted its position in shares of Cooper Companies by 6.6% during the 3rd quarter. Principal Financial Group Inc. now owns 238,305 shares of the medical device company’s stock valued at $26,295,000 after buying an additional 14,687 shares in the last quarter. 24.39% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms recently issued reports on COO. Robert W. Baird reduced their target price on shares of Cooper Companies from $117.00 to $107.00 and set an “outperform” rating for the company in a report on Friday, March 7th. Morgan Stanley decreased their price objective on shares of Cooper Companies from $104.00 to $102.00 and set an “equal weight” rating on the stock in a research report on Friday, December 6th. Piper Sandler restated an “overweight” rating and set a $115.00 target price (down previously from $120.00) on shares of Cooper Companies in a research note on Friday, March 7th. Needham & Company LLC reiterated a “hold” rating on shares of Cooper Companies in a research note on Friday, March 7th. Finally, JPMorgan Chase & Co. lowered their price objective on Cooper Companies from $120.00 to $110.00 and set an “overweight” rating on the stock in a research report on Friday, March 7th. Three equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $111.89.

Cooper Companies Trading Down 1.7 %

COO stock opened at $77.73 on Friday. The firm has a fifty day moving average price of $91.67 and a 200 day moving average price of $99.11. The Cooper Companies, Inc. has a fifty-two week low of $77.05 and a fifty-two week high of $112.38. The firm has a market cap of $15.51 billion, a PE ratio of 39.86, a price-to-earnings-growth ratio of 2.25 and a beta of 1.02. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.12 and a current ratio of 1.91.

Cooper Companies (NASDAQ:COO) last issued its quarterly earnings data on Thursday, March 6th. The medical device company reported $0.92 EPS for the quarter, hitting analysts’ consensus estimates of $0.92. The business had revenue of $964.70 million during the quarter, compared to analysts’ expectations of $981.25 million. Cooper Companies had a net margin of 10.07% and a return on equity of 9.38%. Sell-side analysts anticipate that The Cooper Companies, Inc. will post 3.98 earnings per share for the current fiscal year.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.